Cara Therapeutics, Inc. announced that Frédérique Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, will depart the Company, effective February 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7331 USD | -7.46% | -3.36% | -1.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.33% | 40.08M | |
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-15.09% | 31.99B | |
+51.39% | 24.73B | |
-15.13% | 15.54B | |
-8.63% | 12.05B | |
-40.39% | 12.07B | |
+6.22% | 8.84B | |
-5.15% | 8.3B |
- Stock Market
- Equities
- CARA Stock
- News Cara Therapeutics, Inc.
- Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024